Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT3LH46)

• DTT Name: KRAS G12C mutant (KRAS G12C) DTT Info
• Gene Name: KRAS

Molecule-Related Drug & Molecule List

2 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Adagrasib	DMDV4EP	Non-small-cell lung cancer	2C25	Approved	[1]
Sotorasib	DMLSV74	Non-small-cell lung cancer	2C25	Approved	[2]

4 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JDQ443	DMHI7CQ	Non-small-cell lung cancer	2C25	Phase 3	[3]
LY3499446	DMA1CSR	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
JNJ-74699157	DMY7CW1	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
RG6330	DMSX5NJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]

References

• [1] Clinical pipeline report, company report or official report of Mirati Therapeutics.
• [2] Clinical pipeline report, company report or official report of Amgen.
• [3] Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022 Jun 2;12(6):1500-1517.
• [4] KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020 Sep;89:102070.
• [5] Clinical pipeline report, company report or official report of Roche.